Core Viewpoint - 华检医疗 has experienced a significant stock price increase, with a cumulative rise of over 500% since July 14, 2023, and a current trading price of 11.95 HKD [1] Group 1: Strategic Developments - On August 8, 2023, 华检医疗 announced the launch of its "Global Enhanced Ethereum (ETH) Treasury" strategy and established a global strategic partnership with HashKey Group [1] - A signing ceremony for the global strategic cooperation and the upgrade of the Global Enhanced Ethereum (ETH) Treasury strategy was held on August 11, 2023, at HashKey's office in Hong Kong [1] Group 2: Collaborations and Investments - On July 30, 2023, 华检医疗 signed a strategic cooperation framework agreement with 华大共赢 to jointly establish the "华检华大共赢 Innovative Drug Intellectual Property Tokenization Fund" [1] - The fund aims to invest in 华检医疗's "NewCo+RWA" Web3 trading ecosystem projects in Hong Kong, the United States, and other locations [1] - 华大共赢, initiated by the biotechnology leader 华大基因, has extensive experience and resources in the fields of innovative medicine and drug investment [1]

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, with a cumulative rise of over 500% since July 14, and a current price of 11.95 HKD, reflecting a 19.5% increase at the time of reporting [1] Group 1: Strategic Developments - On August 8, Huajian Medical announced the launch of its "Global Enhanced Ethereum (ETH) Treasury" strategy and formed a global strategic partnership with HashKey Group [1] - A signing ceremony for the global strategic cooperation and the upgrade of the Global Enhanced Ethereum (ETH) Treasury strategy was held on August 11 at HashKey's office in Hong Kong [1] Group 2: Collaborations and Investments - On July 30, Huajian Medical signed a strategic cooperation framework agreement with BGI Win to establish the "Huajian BGI Win Innovative Drug Intellectual Property Tokenization Fund" [1] - This fund aims to invest in Huajian Medical's "NewCo+RWA" Web3 exchange ecosystem projects in Hong Kong, the United States, and other locations [1] - BGI Win, initiated by BGI Genomics, is a corporate venture capital entity with extensive experience and resources in innovative medical and pharmaceutical investments [1]